Vimarsana
Biggest News Aggregation in the World

Page 45 - Eva Mathews News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eva Mathews. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eva Mathews Today - Breaking & Trending Today

GSK lifts annual forecasts again, powered by strong vaccine launch - Vimarsana News

GSK lifts annual forecasts again, powered by strong vaccine launch

By Eva Mathews (Reuters) -GSK raised its full-year profit and sales forecasts for a second time on Wednesday, following the strong launch of its ...

UK regulator approves Pfizer's hair loss drug | WSAU News/Talk 550 AM · 99.9 FM - Vimarsana News

UK regulator approves Pfizer's hair loss drug | WSAU News/Talk 550 AM · 99.9 FM

(Reuters) - Britain's medicines regulator on Wednesday approved Pfizer Inc's drug to treat hair loss caused by an autoimmune disease. The drug, brande...

Source: wsau.com
Broker TP ICAP's Q3 revenue rises on boost from energy and commodities unit - Vimarsana News

Broker TP ICAP's Q3 revenue rises on boost from energy and commodities unit

TP ICAP, the world's biggest inter-dealer broker, reported a 5% rise in third-quarter revenue on Tuesday, as a strong performance in its energy and commodities division helped offset weakness in its...

Related Topics:
Eva MathewsRashmi Aich
GSK signs $1 billion deal for exclusive license to J&J's hepatitis B therapy - Vimarsana News

GSK signs $1 billion deal for exclusive license to J&J's hepatitis B therapy

JNJ-3989 was initially developed by Arrowhead Pharmaceuticals and licensed to Johnson & Johnson-owned Janssen in 2018. Exclusive rights to the therapy will fuel the expansion of GSK's own hepatitis B treatment, bepirovirsen, which is currently in late-stage development, the company said. Hepatitis B, which affects an estimated 300 million people, is a life-threatening viral infection that attacks the liver and patients risk death from cirrhosis and liver cancer.

Source: yahoo.com
GSK says endometrial cancer drug meets primary goal in late-stage trial - Vimarsana News

GSK says endometrial cancer drug meets primary goal in late-stage trial

British drugmaker GSK said on Monday its cancer drug Jemperli met the primary goal of overall survival in patients with primary advanced or recurrent endometrial cancer in a late-stage trial. ...